Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liver-targeted oral testosterone with or without resistance training for sarcopenia
ACTRN12619001408178Phase 3Not yet recruiting
- Sponsor
- University of New South Wales
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of testosterone in Sarcopenia (4 arms), sponsored by University of New South Wales. Primary endpoint: Muscle mass at 6 months. Planned start Jan 2020; status: not yet recruiting.
02
Drugs
testosterone
03
Conditions
Sarcopenia
Beyond the preview
Go deeper on ACTRN12619001408178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001408178.